Preliminary results show that the treatment may reduce strain on both the heart and kidneys.

The ASX healthcare sector has fallen for the week ending May 15, 2026 as the sector's largest stock CSL tumbles on full year FY26 outlook.

Researchers used a blood protein wash to render brain tissue transparent down to 700 µm, witnessing live-firing activity ...

Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industryCommercial launch of AlbuFree™ ...

Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 ...

InVitria, a global leader in chemically defined, animal-origin-free recombinant proteins for advanced therapy manufacturing, announced its participation in the American Society of Gene and Cell ...

An experimental drug, baxdrostat, has shown promising results in treating high blood pressure and chronic kidney disease.

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the ...

"This initiative demonstrates that nutrition and dialysis adequacy are not separate targets, but closely interconnected," she ...

A new experimental drug lowered blood pressure and sharply reduced signs of kidney damage in people with chronic kidney ...

Men’s Health spoke to Novo Nordisk's Thomas Kruse and Jesper Lau, the two chemists responsible for discovering ...

In November 2023 Belarus President Aleksandr Lukashenko went on a working trip to Ostrovets District, Grodno Oblast. He tried ...